List view / Grid view


Meeting access challenges with adaptive trial designs

11 December 2017 | By

With access challenges even after successful but costly development programmes, the industry is under pressure to speed up the clinical development process and produce more for less. Adaptive trial designs, more collaborative working and data sharing could provide a solution in the area of cancer immunotherapy, says Jacqueline Karmel, principal…

Screening In-Depth Focus 2017

11 December 2017 | By

In this In-Depth Focus on Screening, we look at clinically-oriented phenotypic screening and explore how 3-D bioprinted tissues can be used as disease-in-a-dish models for drug screening.

Informatics In-Depth Focus 2017

8 December 2017 | By

In this In-Depth Focus we look at using bioinformatics sequence similarities to optimise repurposing activities; informatics infrastructure in neglected disease research, and machine learning for accelerating drug discovery.

Hit To Lead In-Depth Focus 2017

6 December 2017 | By

In this In-Depth Focus we look at a pragmatic approach to hit validation following biochemical high-throughput screening as well as identification of hits and leads for human African trypanosomiasis.

Clinically-oriented phenotypic screening: understanding and exploiting the dynamic nature of the cancer cell phenotype

6 December 2017 | By ,

Understanding the cancer cell phenotype is central to both cancer diagnosis and treatment. Discrete molecular signatures among cancer phenotypes underpin patient stratification, while rapid methods for detailed phenotyping in the clinic (via liquid biopsies and tumour imaging) enable the delivery of personalised, effective precision medicines to the cancer patient...

Flow cytometry – accelerating neuroscience research

18 September 2017 | By

Flow cytometry continues to evolve at a fast pace and provides neuroscientists with the ability to perform many highly-specialised assays simultaneously. It meets the demands of cutting-edge research in neuroscience that has allowed researchers to isolate particular neural cells from heterogeneous population and catalogue its molecular or physical features...

Expert view: Innovations in 3D

15 September 2017 | By

Physiologically relevant models to evaluate the effects of drug candidates early in the drug discovery and development process are becoming increasingly important to develop. Various 3D cell/tissue models have emerged offering relevant environment for ex vivo assays, but significant progress is required to streamline and automate the end-to-end workflow. Several…